Comparative Study on the Application of Mesenchymal Stromal
Cells Combined with Tricalcium Phosphate Scaffold into Femoral
Bone Defects

J 2018

Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects

SPONER, P., T. KUCERA, J. BRTKOVA, K. URBAN, Z. KOCI et. al.

Základní údaje

Originální název

Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects

Autoři

SPONER, P., T. KUCERA, J. BRTKOVA, K. URBAN, Z. KOCI, P. MERICKA, A. BEZROUK, S. KONRADOVA, A. FILIPOVA a S. FILIP

Vydání

Cell Transplantation, THOUSAND OAKS, SAGE PUBLICATIONS INC, 2018, 0963-6897

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.477

DOI

http://dx.doi.org/10.1177/0963689718794918

UT WoS

000446855200005

Klíčová slova česky

mesenchymal stromal cells; scaffold; bone defect; cell therapy

Klíčová slova anglicky

mesenchymal stromal cells; scaffold; bone defect; cell therapy

Štítky

Excelence Science, FN HK, RIV, user

Změněno: 7. 12. 2021 13:03, Bc. Hana Vladíková, BBA

Anotace

V originále

This prospective study sought to evaluate the healing quality of implanted ultraporous beta-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received beta-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received beta-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous beta-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman-Halton modification of the Fischer's exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with beta-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment.

Návaznosti

90090, velká výzkumná infrastruktura

Název: CZECRIN II

Citovat

SPONER, P., T. KUCERA, J. BRTKOVA, K. URBAN, Z. KOCI, P. MERICKA, A. BEZROUK, S. KONRADOVA, A. FILIPOVA a S. FILIP. Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects. Cell Transplantation. THOUSAND OAKS: SAGE PUBLICATIONS INC, 2018, roč. 27, č. 10, s. 1459-1468. ISSN 0963-6897. Dostupné z: https://dx.doi.org/10.1177/0963689718794918.

@article{1807995,
   author = {Sponer, P. and Kucera, T. and Brtkova, J. and Urban, K. and Koci, Z. and Mericka, P. and Bezrouk, A. and Konradova, S. and Filipova, A. and Filip, S.},
   article_location = {THOUSAND OAKS},
   article_number = {10},
   doi = {http://dx.doi.org/10.1177/0963689718794918},
   keywords = {mesenchymal stromal cells; scaffold; bone defect; cell therapy},
   language = {eng},
   issn = {0963-6897},
   journal = {Cell Transplantation},
   note = {RIV/00216208:11130/18:10380944},
   title = {Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects},
   url = {https://journals.sagepub.com/doi/10.1177/0963689718794918},
   volume = {27},
   year = {2018}
}

TY  - JOUR
ID  - 1807995
AU  - Sponer, P. - Kucera, T. - Brtkova, J. - Urban, K. - Koci, Z. - Mericka, P. - Bezrouk, A. - Konradova, S. - Filipova, A. - Filip, S.
PY  - 2018
TI  - Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects
JF  - Cell Transplantation
VL  - 27
IS  - 10
SP  - 1459-1468
EP  - 1459-1468
PB  - SAGE PUBLICATIONS INC
SN  - 09636897
N1  - RIV/00216208:11130/18:10380944
KW  - mesenchymal stromal cells
KW  - scaffold
KW  - bone defect
KW  - cell therapy
UR  - https://journals.sagepub.com/doi/10.1177/0963689718794918
N2  - This prospective study sought to evaluate the healing quality of implanted ultraporous beta-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received beta-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received beta-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous beta-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman-Halton modification of the Fischer's exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with beta-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment.
ER  -

SPONER, P., T. KUCERA, J. BRTKOVA, K. URBAN, Z. KOCI, P. MERICKA, A. BEZROUK, S. KONRADOVA, A. FILIPOVA a S. FILIP. Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects. \textit{Cell Transplantation}. THOUSAND OAKS: SAGE PUBLICATIONS INC, 2018, roč.~27, č.~10, s.~1459-1468. ISSN~0963-6897. Dostupné z: https://dx.doi.org/10.1177/0963689718794918.

Podrobný výpis o publikaci